The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Combination of transarterial therapy with sorafenib for hepatocellular carcinoma.
R. Cabrera
Consultant or Advisory Role - Bayer (U)
Honoraria - Bayer
Research Funding - Bayer
D. S. Pannu
No relevant relationships to disclose
J. Caridi
Honoraria - AngioDynamics; Bayer
R. Firpi
No relevant relationships to disclose
C. Soldevila-Pico
No relevant relationships to disclose
G. Morelli
No relevant relationships to disclose
V. Clark
No relevant relationships to disclose
T. J. George
No relevant relationships to disclose
D. Nelson
Consultant or Advisory Role - Bayer (U)
Honoraria - Bayer
Research Funding - Bayer